Fig. 2

Effects of LPS treatment on the phenotype of splenic macrophages from tPA^−/− mice. A Representative flow cytometry gating strategy used for quantification of spleen macrophages (F4/80⁺ CD11b⁺), expressing MHCII molecules or not (F4/80⁺ CD11b⁺ MHCII^+or−) and costimulatory molecules (F4/80⁺ CD11b⁺ MHCII^+or− CD80⁺ CD86⁺). B Frequency of macrophages (Sham WT n = 9; Sham tPA^−/−; LPS WT; LPS tPA^−/− n = 10). C Frequency of MHCII⁻ macrophages (F4/80⁺ CD11b⁺ MHCII⁻) and of costimulatory molecule expressing cells (F4/80⁺ CD11b⁺ MHCII⁻ CD80⁺ CD86⁺), (Sham WT n = 9; Sham tPA^−/−; LPS WT; LPS tPA^−/− n = 10). D Frequency of MHCII⁺ macrophages (F4/80⁺ CD11b⁺ MHCII⁺), (Sham WT n = 9; Sham tPA^−/−; LPS WT; LPS tPA^−/− n = 10), MFI quantification of MHCII on MHCII⁺ macrophages (Sham WT n = 9; Sham tPA^−/−; LPS WT; LPS tPA^−/− n = 10) and frequency of MHCII⁺ macrophages expressing costimulatory molecules (F4/80⁺ CD11b⁺ MHCII⁺ CD80⁺ CD86⁺), (Sham WT n = 9; Sham tPA^−/−; LPS WT; LPS tPA^−/− n = 10). E MFI quantification of CD80 (Sham WT n = 8; Sham tPA^−/−; LPS WT n = 10; LPS tPA^−/− n = 9), CD86 (Sham WT n = 8; Sham tPA^−/− n = 9, LPS WT; LPS tPA^−/− n = 10) and CD11b molecules (Sham WT n = 8; Sham tPA^−/−; LPS WT; LPS tPA^−/− n = 10) on MHCII⁻ macrophages. F MFI quantification of CD80 (Sham WT n = 8; Sham tPA^−/−; LPS WT n = 10; LPS tPA^−/− n = 9), CD86 and CD11b molecules (Sham WT n = 9; Sham tPA^−/−; LPS WT; LPS tPA^−/− n = 10) on MHCII⁺ macrophages. Data are shown as individual animals with mean ± SD, two-way ANOVA with Bonferroni’s post-hoc